Longterm anti-tumor necrosis factor-α treatment in patients with refractory rheumatoid arthritis: Relationship between insulin resistance and disease activity

Journal of Rheumatology

Volumn 35, Issue 2, 2008, Pages 355-357

  Seriolo, Bruno ^a   Ferrone, Carmela ^a   Cutolo, Maurizio ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; AGE DISTRIBUTION; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; LETTER; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

AGED; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; INSULIN; INSULIN RESISTANCE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 39549102650     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (12)

1. Solomon DH, Karlson EW, Rimm EB, et al. Cardiovascular morbidity and mortality in patients with rheumatoid arthritis. Circulation 2003;107:1303-07.
2. Van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis. An extraarticular feature of rheumatoid arthritis? Arthritis Rheum 2002;46:862-73.
3. Seriolo B, Paolino S, Ferone C, Cutolo M. Effects of etanercept or infliximab treatment on lipid profile and insulin resistance in patients with refractory rheumatoid arthritis. Clin Rheumatol 2007;26:1799-800.
4. Dessein PH, Stanwix AE, Joffe BI. Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response-related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res 2002;4:R5.
5. Dessein PH, Joffe BI, Stanwix AE. Effects of disease modifying agents and dietary intervention on insulin resistance and dyslipidemia in inflammatory arthritis: a pilot study. Arthritis Res 2002;4:R12.
6. Dessein PH, Joffe BI, Stanwix A, Botha AS, Moomal Z. The acute phase response does not fully predict the presence of insulin resistance and dyslipidemia in inflammatory arthritis. J Rheumatol 2002;29:462-6.
7. Seriolo B, Paolino S, Ferrone C, Cutolo M. Impact of long-term anti-TNFα treatment on insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007; (in press).
8. Dessein PH, Norton GR, Woodiwiss AJ, et al. Independent role of conventional cardiovascular risk factors as predictors of C-reactive protein concentrations in rheumatoid arthritis. J Rheumatol 2007;34:681-8.
9. Chung CP, Oeser A, Solus JF, et al. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis 2007 Jan 29; Epub ahead of print.
10. Bonora E, Kiechl S, Willeit J, et al. Prevalence of insulin resistance in metabolic disorders. The Bruneck Study. Diabetes 1998;47:1643-9.
11. Dessein PH Stanwix AE, Joffe BI, et al. Quantitative Insulin Sensitivity Check Index: a simple accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000;85:2402-10.
12. Gonzalez-Gay MA, De Matias M, Gonzalez-Juanatey C, et al. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006;24:83-6.